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Abstract
Fosfomycin is an oral antibiotic with activity against multidrug re-
sistant organisms, including vancomycin-resistant enterococcus (VRE) 
and extended-spectrum β-lactamase (ESBL) producing Enterobacteria-
ceae. However, there is currently no information describing efficacy of 
fosfomycin compared to other agents for healthcare associated UTIs. 
Additionally, there is minimal information characterizing the potential 
cost savings with utilization of fosfomcyin versus traditional therapies. 
This retrospective study evaluated clinical and economic outcomes of 
fosfomycin compared to matched controls. The controls were before 
the addition of fosfomycin to hospital formulary with recommended 
prescribing criteria. The fosfomycin group consisted of patients who 
were admitted to the hospital after the addition of fosfomycin to the 
hospital formulary with recommended prescribing criteria. Patients 
receiving fosfomycin for the treatment of UTI were matched to con-
trol patients based on pathogen, renal function, and presence of a 
lower UTI. A total of 86 patients were evaluated. The majority of 
patients received fosfomycin for the treatment of VRE (45.6%) and 
ESBL producing Enterbacteriaceae (16.3%) UTIs. Patients with a com-
bination of allergies or documented resistance to first line agents also 
received fosfomycin to treat Enterococcus (25.6%), Enterobacteriaceae 
(7.8%), or polymicrobial UTIs (4.7%). Doxycycline, nitrofurantoin, sulfa-
methoxazole/trimethoprim, meropenem, and linezolid were the most 
common antibiotics prescribed in the control group. The average days 
of treatment were lower in the fosfomycin group (2.93 vs. 7.19 days, 
p<0.0001). Fosfomcyin was associated with similar clinical success ra-
tes (95 vs. 95%, p>0.99) and recurrence rates (4.7 vs. 4.7%, p>0.99). 
Clinical Efficacy of Fosfomycin for the Treatment of 
Complicated Lower Tract and 
Uncomplicated Urinary Tract Infections
 ORIGINAL 
Jerod L. Nagel1,3, Laraine Washer2, Anjly Kunapuli1,3, 
Jennifer Heidmann3, Jennifer Pisani3, Tejal Gandhi2
1  University of Michigan Hospitals 
and Health System, Department of 
Pharmacy, Ann Arbor, Michigan, USA.
2  University of Michigan Hospitals and 
Health System, Division of Infectious 
Diseases, Ann Arbor, Michigan, USA.
3  University of Michigan College of 
Pharmacy, Ann Arbor, Michigan, USA.
Contact information:
Jerod L. Nagel.
Running Head: Fosfomycin for Treatment 
of Urinary Tract Infections.
Address: 1111 E Catherine Street, Rm 
300. Ann Arbor, MI 48109.
nageljl@med.umich.edu
Keywords
UTI, Fosfomycin, VRE, ESBL.
INTERNATIONAL ARCHIVES OF MEDICINE
Section: Microbiology 
ISSN: 1755-7682 J
2015
Vol. 8 No. 151
doi: 10.3823/1750
This article is available at: www.intarchmed.com and www.medbrary.com 2
Background
In recent years, multi-drug resistant (MDR) urinary 
tract infections (UTI) caused by extended spectrum 
β-lactamase (ESBL) producing Enterobacteriaceae 
and vancomycin-resistant Enterococci (VRE) have 
become more prevalent. [1-3] Due to high resistance 
rates to oral antibiotics, VRE and ESBL UTIs are com-
monly treated with intravenous antibiotics which 
are more expensive and inconvenient for patients. 
[2, 4] Thus, there is a need for less expensive and 
effective alternative antibiotics for the treatment of 
VRE and ESBL UTIs. [5-9] Fosfomycin tromethamine 
is a synthetic, broad spectrum, bactericidal antibiotic 
that works by inhibiting pyruvyl transferase during 
bacterial cell wall synthesis, and it may also decrea-
ses bacterial adherence to epithelial cells in the uri-
nary tract. [10] Fosfomycin is available as an orally 
administered single-dose 3 gram sachet that is mi-
xed with water. [10] Some reports utilize 3-doses of 
fosfomycin for the treatment of complicated lower-
tract UTIs, but efficacy and safety of this regimen 
has never been compared to single-dose regimens. 
[11] Fosfomycin has demonstrated efficacy in both 
in vitro and in vivo studies for treating UTIs caused 
by ESBL-producing Enterobacteriaceae, [12-15] whi-
le in vitro studies have shown high susceptibility 
of VRE to fosfomycin with susceptibilities of 98%. 
[5-7] Clinical data are limited to bolster the use of 
fosfomycin; however, a recent study showed high 
microbiological cure rates and in vitro susceptibility 
of VRE and ESBL UTI isolates to fosfomycin. [16] 
In 2010, the University of Michigan Health System 
(UMHS) Antimicrobial Stewardship Program intro-
duced a guideline recommending the use of fos-
fomycin tromethamine for the treatment of lower 
UTIs caused by VRE or ESBL producing organisms 
that are resistant to other oral antibiotics. 
Objectives
The aim of this study was to evaluate the clinical 
efficacy of fosfomycin for the definitive treatment of 
VRE and ESBL lower tract UTIs in addition to those 
UTIs caused by non-VRE Enterococci and non-ESBL 
Enterobacteriaceae that are unable to be treated 
with oral antibiotics due to patient allergies or re-
sistance. This study also determined cost savings 
to the institution following implementation of the 
guideline. 
Methods
This retrospective matched cohort study was con-
ducted at the University of Michigan Health Sys-
tem, a 930-bed academic hospital, and received 
Institutional Review Board approval. Clinical outco-
mes were evaluated for patients who received 
fosfomycin from January 1, 2011 to December 31, 
2011, and compared with a matched control group 
who received alternative treatment regimens during 
2009-2010. The fosfomycin group included all pa-
tients who received a dose of fosfomycin in the 
year 2011 after implementation of an institutional 
guideline which provided treatment recommenda-
tions for uncomplicated and complicated lower UTI. 
This guideline recommended the use of fosfomycin 
Additionally, the mean antibiotic cost per patient was lower in the 
fosfomycin group ($106.74 vs. $269.55). Adding fosfomycin to for-
mulary resulted in similar clinical success rates and lower cost for the 
treatment of complicated lower and uncomplicated UTIs.
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tromethamine for the treatment of lower UTIs cau-
sed by VRE or ESBL producing organisms that are 
resistant to other oral antibiotics. The patients in the 
fosfomycin group were matched to historical con-
trols from 2009 and 2010 based on organism and 
creatinine clearance (CrCl) greater than 50 ml/min. 
Patients were considered to have a UTI if patient 
had documented UTI-specific symptoms (dysuria, 
frequency or urgency) in combination with elevated 
white blood cells per high powered field on urinaly-
sis. Patients were also considered to have a UTI if 
the patient had a condition which made UTI specific 
symptoms undetectable (presence of urinary cathe-
ter, altered mental status, quadrapalegic). This study 
defined UTI as the following: physician diagnosed 
patient as having a UTI, presence of documented 
symptoms or abnormal urinalysis, and the patient 
received treatment with antibiotics. Inclusion criteria 
consist of patients greater than or equal to 18 years 
old who received treatment for a complicated or 
uncomplicated lower UTI caused by Enterococcus or 
Enterobacteriacae. Patients were excluded if preg-
nant, or recent renal transplant. 
UTI symptoms defined as dysuria or increased 
urgency or frequency of urination were collected 
when available. Urinalysis was analyzed for white 
blood cell count greater than 10 per high powered 
feild, positive leukocyte esterase, and positive nitrite. 
Urine culture results were collected including the 
organism isolated, number of organisms (CFU/ml), 
susceptibility to fosfomycin, and the date of culture. 
All organisms identified in the urine culture were 
collected. Routine fosfomycin susceptibility testing 
was performed for all VRE isolates from urine using 
Kirby Bauer and upon request for other organisms. 
Urine culture results with the same organism were 
documented for all repeat positive cultures within 
30 days of the original culture. Any repeat cultu-
res were further investigated to determine whether 
colonization or infection were present. In the fos-
fomycin group, antibiotics received within 2 days of 
fosfomycin therapy were recorded. In the control 
group, all antibiotics used to treat the UTI were re-
corded. Antibiotic data collected included dose, fre-
quency, duration, and total grams administered to 
the patient. Dosing recommendations for fosfomy-
cin in the UMHS guidelines include 3-gram single 
dose therapy for uncomplicated UTIs and 1-3 doses 
every 48 hours for complicated UTIs. 
The primary endpoint was clinical success of UTI 
treatment, which was defined as having a urine cul-
ture within 30 days of the original culture that was 
not positive for the same organism. As this was a 
retrospective study, patients were not required to 
have a repeat urine culture. The secondary endpoint 
for the study was the total cost of antibiotic therapy 
for each patient for the treatment of the UTI using 
the total amount of antibiotic in grams received 
by the patient. The average wholesale price (AWP) 
of each medication was used in the cost analysis. 
Continuous variables were compared using the Stu-
dent T test and categorical variables were evaluated 
using Chi-square and Fisher’s exact test. 
Results 
A total of 86 patients were evaluated which inclu-
ded 43 patients in the fosfomycin group and 43 pa-
tients in the control group. Both patient demogra-
phics and UTI characteristics were generally similar 
between the fosfomycin and control groups (Table 
1). Patients in the control group had significantly 
higher CrCl (79 vs. 58 ml/min, P<0.001). Treatment 
of resistant pathogens made up the largest pro-
portion of fosfomycin use with 45% of patients 
receiving treatment for VRE and 16% for ESBL-
producing Enterbacteriaceae UTIs. Due to a com-
bination of allergies, resistance, or contraindications 
to commonly prescribed oral antibiotics, the remai-
ning patients received treatment for non-VRE Ente-
rococcus (25%), non-ESBL Enterbacteriaceae (8%), 
and polymicrobial (5%) UTIs. The most common 
dosing regimen for fosfomycin received by 81.4% 
of patients (35/43) was 3 grams orally for one dose. 
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The remaining 19% (8/43) received a variety of mul-
tiple dose regimens with 3 grams every 48 hours 
for three doses being the most common regimen. 
Nitrofurantoin, sulfamethoxazole/trimethoprim, and 
doxycycline were the most utilized antibiotics in 
the control group (Table 2). The average days of 
treatment were lower in the fosfomycin group (2.93 
vs. 7.19 days, p<0.0001).
The clinical success rate was identical in both 
the fosfomycin and control groups with 95% of 
patients (41/43) not having a repeat positive culture 
of the same organism within 30 days. Both groups 
also had 2 patients (5%) with repeat positive cultu-
res and hospital readmission for UTI within 30 days. 
One patient from the fosfomycin group had a re-
peat positive culture for VRE faecium, and the other 
patient had a repeat urine culture positive for ESBL 
Escherichia coli and Klebsiella pneumoniae. In the 
control group, one patient had a repeat urine cul-
Table 1. Patient Characteristics.
Independent 
variables
Fosfomycin 
N=43
Control 
N=43
p-value
Demographics
Age 63.2 60.2 0.44
Female 35 (81%) 28 (65%) 0.14
Creatinine clearance 
(ml/min)
58 79 < 0.001
UTI Characteristics
Complicated lower 
tract UTI 
34 (79%) 41 (95%) 0.049
Documented UTI 
symptoms
29 (67%) 24 (56%) 0.38
WBC > 10 in UA 25 (68%) 25 (68%) > 0.99
Leukocyte esterase 
positive
32 (74%) 29 (67%) 0.48
Nitrate positive 5 (12%) 5 (12%) > 0.99
Table 2. Antibiotic utilization including both empiric and definitive UTI therapy.
Antibiotic
Antibiotic 
Utilization 
Fosfomycin Group
Antibiotic 
Utilization 
Control Group
Antibiotic Days 
Fosfomycin Group
Antibiotic Days 
Control Group
Ceftriaxone 11 (26%) 5 (12%) 2.2 2
Ciprofloxacin/Levofloxacin 6 (14%) 9 (21%) 2.8 3.9
Meropenem 5 (12%) 3 (7%) 1 5.3
Nitrofurantoin 2 (5%) 13 (30%) 3 4
Sulfamethoxazole/Trimethoprim 2 (5%) 12 (28%) 2 3.2
Cefepime 2 (5%) 0 (0%) 6.5 0
Doxycycline 2 (5%) 9 (21%) 3 6
Tigecycline 2 (5%) 2 (5%) 1 6.5
Ertapenem 2 (5%) 3 (7%) 2.5 6.3
Zosyn 0 (0%) 5 (12%) 0 5.2
Ampicillin/Amoxicillin 1 (2%) 10 (23%) 4 4.2
Daptomycin 0 (0%) 1 (2%) 0 7
Gentamicin 1 (2%) 1 (2%) 1 1
Linezolid 0 (0%) 3 (7%) 0 8
Other 4 (9%) 7 (16%) 1.5 1.1
Average days of antibiotic therapy 2.93 7.19
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ture positive for VRE faecium, and the other patient 
had ESBL Escherichia coli on a repeat urine culture. 
The mean antibiotic cost per patient was lower 
in the fosfomycin group ($106.74 vs. $269.55). A 
reduction in cost of antibiotic therapy was seen in 
patients treated with fosfomycin for VRE and ESBL 
UTIs with cost savings of $162.81 per patient trea-
ted. Although an overall cost savings was seen bet-
ween groups, there was a higher cost associated 
with using fosfomycin for the treatment of non-VRE 
Enterococcus and non-ESBL Enterbacteriaceae UTIs 
(Figure 1). 
Discussion
This study reiterates the clinical utility of fosfomy-
cin against ESBL producing Enterbacteriaceae UTIs, 
as seen in previous studies, and establishes in vivo 
activity against VRE. [3, 6-13, 16-18 ]In addition, this 
is the first study to compare clinical outcomes of 
fosfomycin in the hospital setting for MDR UTIs and 
associated antibiotic costs. Neuner et al. conducted 
a retrospective chart review of 41 patients treated 
with fosfomcycin who had a MDR UTI from 2006 to 
2010 but did not compare outcomes to other anti-
biotics traditionally prescribed for these pathogens. 
[16] UTI pathogens in the Neuner study included VRE 
and ESBL producers, and fosfomycin demonstrated 
in vitro susceptibility of 86%. [16] Microbiologic cure 
was reported in 71% of patients with VRE and ESBL 
UTIs, and in our study population the cure rate was 
95%. [16] The Neuner et al. defined patient relapse 
as developing a UTI with the same organism within 
30 days, as we did in our study. [16] In their study, 
24% of patients had a relapse, whereas 5% of our 
patients had a UTI with the same organism within 
30 days of the initial urine culture. [16] Neuner et 
al. concluded that fosfomycin has MDR UTI in vitro 
activity but that more data is needed to assess the 
use of fosfomycin for treating MDR UTIs. [16] The 
differences in clinical success and relapse rates could 
be due to different populations, as we evaluated 
all patients who received fosfomyicn, and the study 
conducted by Neuner and colleagues included only 
Figure 1:  Mean acquisition cost of antibiotic therapy per patient.
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patients with MDR pathogens. Additionally, a re-
trospective study by Reid et al. was conducted using 
patient data from 2010 to 2011. [19] They specifically 
looked at 14 cases of gram-negative UTIs in patients 
who had received a kidney transplant. [19] 57% of 
patients in their study were administered 3 doses 
of fosfomycin, whereas only 11.6% of our patients 
received 3 doses. [18] Their study defined recurrence 
as having a UTI with the same organism within 3 
months of the initial diagnosis, whereas we defined 
clinical failure as infection with the same organism 
within 30 days of the original culture. [18] Reid et 
al. reported 54% of patients had recurrence of their 
UTI. [19] The difference in recurrence rates between 
the 3 studies is likely due to differences in sample 
size, UTI pathogens, inclusion population, definition 
of recurrence, and patient specific factors, such as 
immunosuppression and comorbid conditions. [19] 
At the UMHS, VRE susceptibilities are routinely 
tested, but ESBL susceptibilities are tested only upon 
request. There are no official E. faecium breakpoints 
for fosfomycin, but E. faecalis fosfomycin breakpoints 
were used for both species at our institution. Our 
methodology focused on efficacy of fosfomycin 
versus other agents, and if a patient meets criteria 
for fosfomycin use, then we recommend fosfomycin 
instead of expensive antibiotics such as daptomycin 
or linezolid. Utilization of fosfomycin according to 
UMHS guideline may improve VRE and ESBL UTI 
treatment by shortening duration of therapy and 
decreasing cost while maintaining effective clinical 
outcomes.
Our study has several important limitations. The 
data was obtained from a single-center and may 
affect generalizability to other institutions. The re-
trospective study design relied on the physicians’ 
ability to correctly distinguish between UTI and as-
ymptomatic bacteriuria. Our ability to distinguish 
between asymptomatic bacteriuria and UTI was li-
mited because symptoms attributable to a UTI were 
not documented in the chart for 33% of patients 
in the fosfomycin group and 46% of patients in 
the control group. However, patients presented with 
other potential signs of infection including leuko-
cytosis, fever, mental status changes, or abnormal 
urinalysis. Thus, we’ve made reasonable attempts 
to characterize patients with UTI, with the unders-
tanding that not all patients can communicate UTI-
specific symptoms, and physician documentation of 
UTI-specific symptoms in the medial chart is not 
optimal. [20] 
We were also not able to demonstrate efficacy 
of fosfomycin alone because we analyzed efficacy 
for the entire antibiotic regimen from empiric to 
definitive therapy. Patient groups were small when 
treatment costs were analyzed by pathogen, and 
various patient factors may have skewed the cost re-
sults. A final limitation is that follow-up urine cultu-
res to evaluate clinical efficacy were only identified 
if the urine culture was performed at our institution. 
Even with these limitations, this study supports the 
efficacy and cost-effectiveness of fosfomycin for 
treatment of lower UTI caused by VRE or ESBL pro-
ducing organisms.
Conclusion
In conclusion, fosfomycin for the treatment of lower 
UTIs was as efficacious and in some cases more cost-
effective compared to other antibiotics. Treatment 
with fosfomycin was also associated with significant 
cost savings and fewer days of antibiotic therapy. 
Fosfomycin should be considered for the treatment 
of VRE and ESBL lower UTIs that are resistant to 
inexpensive oral antibiotics. 
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